Treating Multiple Myeloma in Japan/Asia-Pacific Region
Interactive discussions and expert insights on the latest updates and remaining challenges
Overview
In recent years, progress in the understanding of multiple myeloma has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Multiple Myeloma Academy to help physicians who treat multiple myeloma bridge the gap between innovation and implementation of patient care.
Date and Location
March 25–26, 2026, Virtual Meeting
Chair
Rafael Fonseca, MD
Mayo Clinic Cancer Center, USA
|
Agenda |
This 2-day interactive virtual meeting with global experts will focus on the treatment of patients with relapsed/refractory multiple myeloma (RRMM) in various countries within the Asia/Pacific region. Day 1: Follow interactive presentations and case-based discussions with your peers on the latest updates for assessments and treatments for patients with MM after initial therapy, including the role of bispecific antibodies in RRMM and immunotherapy sequencing across the current and potential future treatment landscapes. Engage with the faculty in panel discussions on therapeutic options for the later-line treatment settings in MM. Discuss regional case studies in late-stage RRMM with your colleagues. Day 2: Join to learn more about the current MM treatment landscape and discuss patient eligibility for CAR T-cell therapy, real-world evidence (RWE) around earlier use of CAR T-cell therapy, and treatment options for non-CAR T-cell candidates. Interact with faculty during a panel discussion on patient access and regional challenges for optimal patient care. |
Day 1: Wednesday, March 25, 2026
17.00 – 20.00 China Standard Time
| Time | Topic | Speaker |
| 17.00 – 17.10 | Welcome and Meeting Overview • Introduction to audience response system (ARS) |
Rafael Fonseca, MD |
| 17.10 – 17.45 | Overview of Later-Line Relapsed/Refractory Multiple Myeloma (RRMM) Treatment and Management | |
| 17.45 – 18.20 | Bispecific Antibodies in RRMM | |
| 18.20 – 18.35 | Break | |
| 18.35 – 19.05 | Immunotherapy Sequencing in RRMM: Current and Future Landscape | |
| 19.05 – 19.40 | Panel Discussion: Patient Case Debate – RRMM | |
| 19.40 – 20.00 | Final ARS Questions and Concluding Remarks | Rafael Fonseca, MD |
Day 2: Thursday, March 26, 2026
17.00 – 20.00 China Standard Time
| Time | Topic | Speaker |
| 17.00 – 17.10 | Welcome and Meeting Overview • Introduction to audience response system (ARS) |
Rafael Fonseca, MD |
| 17.10 – 17.30 | Overview of Relapsed/Refractory Multiple Myeloma (RRMM) Treatment: Early Lines of Therapy | |
| 17.30 – 17.50 | CAR T-Cell Therapy in RRMM: Impact of Earlier Use and Real-World Data | |
| 17.50 – 18.10 | Treatment Options for Non–CAR T-Cell Candidates | |
| 18.10 – 18.25 | Break | |
| 18.25 – 19.20 | Patient Case Discussion: RRMM | Regional case presenter All faculty |
| 19.20 – 19.50 | Future Directions in Early Lines of Therapy for RRMM | |
| 19.50 – 20.00 | ARS Questions and Session Close | Rafael Fonseca, MD |
